Arvinas downgraded to Market Perform from Outperform at Leerink
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
17 hours ago
- Yahoo
Sappi concludes $500m expansion project at Somerset Mill in Maine, US
Sappi North America has announced the completion of Project Elevate, which involved a $500m investment to convert and expand Paper Machine No. 2 (PM2) at its Somerset Mill located in Maine, US. This development comes as a response to the growing demand for quality, fibre-based sustainable packaging solutions. The company is now poised to deliver commercial products to customers, with qualification processes underway and full production volumes expected by 2026. The expansion doubles the production capacity of PM2 and transforms Somerset into an advanced site for producing solid bleached sulfate (SBS) paperboard. Sappi North America president and CEO Michael Haws said: 'With PM2, we have delivered the largest rebuild in our company's history, doubling the machine's capacity and positioning Somerset as a leader in sustainably manufactured paperboard. 'This investment goes beyond machinery; it's about laying the foundation for long-term innovation, sustainable growth, and lasting impact.' As Sappi North America gears up for full-scale production, the investment is expected to yield an annual capacity of approximately 470,000 tonnes (t) of SBS paperboard. This includes a range of high-performance grades suitable for folding cartons, cups, and foodservice boards. The company will now be able to support both domestic and international packaging customers with the latest technology. Sappi North America manufacturing vice-president Kirk Ross said: 'Product from the new machine is now commercially available, delivering the same high standards of quality and performance our customers expect, while expanding our range of applications. 'With increased capacity and a focus on improved service, we're able to meet growing demand with greater speed, consistency, and responsiveness.' The PM2 conversion began in 2022, after the PM1 rebuild in 2018. "Sappi concludes $500m expansion project at Somerset Mill in Maine, US" was originally created and published by Packaging Gateway, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Upturn
17 hours ago
- Business Upturn
Global Dermal Fillers Market is Predicted to Reach ~USD 12 Billion by 2032
By GlobeNewswire Published on July 31, 2025, 22:00 IST New York, USA, July 31, 2025 (GLOBE NEWSWIRE) — Global Dermal Fillers Market is Predicted to Reach ~USD 12 Billion by 2032 | DelveInsight The demand for dermal fillers is influenced by several major factors. First, the global increase in cosmetic procedures is largely driven by an aging population and a heightened desire to preserve a youthful look, coupled with growing aesthetic awareness. Additionally, there is a notable trend toward minimally invasive cosmetic treatments because they offer greater convenience, quicker recovery, and lower costs compared to traditional surgical options. DelveInsight's Dermal Fillers Market Insights report provides the current and forecast market analysis, individual leading dermal fillers companies' market shares, challenges, dermal fillers market drivers, barriers, trends, and key market dermal fillers companies in the market. Key Takeaways from the Dermal Fillers Market Report As per DelveInsight estimates, North America is anticipated to dominate the global dermal fillers market during the forecast period. In the material segment of the dermal fillers market, the hyaluronic acid (HA) category accounted for the largest market share in 2024. Notable dermal fillers companies such as AbbVie Inc., Galderma, Merz Pharma, Tiger BioSciences, Teoxane SA, Crown Laboratories, Inc., Prollenium Medical Technologies, Inc., Johnson & Johnson Services, Inc., Anika Therapeutics, Inc., Fillmed, VIVACY Laboratories, Sinclair, Medytox, HUGEL, Inc., Ipsen Pharma, Evolus, Inc., Symatese, LG Chem, KORU Pharma Co., LTD., BIOPLUS CO., LTD., and several others are currently operating in the Dermal Fillers market. and several others are currently operating in the Dermal Fillers market. In February 2025, Crown Laboratories, Inc., a privately held global leader in skincare innovation, announced the successful acquisition of Revance Therapeutics, Inc., a pioneering biotechnology company specializing in dermal fillers. Through this acquisition, Crown significantly enhanced its product portfolio and expanded its global presence in the dermal fillers market, particularly with RHA Redensity™ and its range of RHA® 2, RHA® 3, and RHA® 4-based dermal fillers. a privately held global leader in skincare innovation, announced the successful acquisition of Revance Therapeutics, Inc., a pioneering biotechnology company specializing in dermal fillers. Through this acquisition, Crown significantly enhanced its product portfolio and expanded its global presence in the dermal fillers market, particularly with RHA Redensity™ and its range of RHA® 2, RHA® 3, and RHA® 4-based dermal fillers. In October 2024, Allergan Aesthetics, an AbbVie company, announced the national availability of JUVÉDERM® VOLUMA® XC for the treatment of temple hollowing. This hyaluronic acid (HA) filler is approved for addressing moderate to severe temple hollowing in adults over 21. As the leading HA dermal filler brand preferred by both patients and providers, the JUVÉDERM® Collection of Fillers now offers the broadest range of treatment indications to help patients achieve their aesthetic goals. To read more about the latest highlights related to the dermal fillers market, get a snapshot of the key highlights entailed in the Global Dermal Fillers Market Report Dermal Fillers Overview Dermal fillers are injectable substances used to restore volume, smooth out wrinkles, and enhance facial contours. Composed primarily of hyaluronic acid, calcium hydroxylapatite, poly-L-lactic acid, or polymethylmethacrylate beads, these fillers work by replenishing lost volume in the skin and stimulating collagen production. They are commonly used to treat areas such as the cheeks, lips, nasolabial folds, and under-eye hollows, providing a non-surgical alternative for facial rejuvenation. The effects of dermal fillers are temporary, lasting anywhere from six months to two years, depending on the type of filler and individual patient factors. The procedure is minimally invasive, typically performed in a clinical setting with little to no downtime. Local anesthesia or numbing agents may be applied to minimize discomfort during injection. While generally safe when administered by trained professionals, dermal fillers can have side effects, including swelling, bruising, redness, and in rare cases, complications like vascular occlusion or infection. Due to these risks, proper patient assessment and adherence to safety protocols are essential. Increasingly popular for their convenience and effectiveness, dermal fillers remain a leading option in cosmetic dermatology for individuals seeking subtle yet noticeable aesthetic improvements. Dermal Fillers Market Insights North America is expected to dominate the dermal fillers market in the coming years, supported by several critical factors. This leadership is largely driven by the growing number of cosmetic procedures, which are influenced by an aging population and a strong desire to maintain youthful looks. Additionally, the preference for minimally invasive aesthetic treatments, combined with a robust healthcare infrastructure, has accelerated market expansion. Rising awareness and widespread acceptance of cosmetic enhancements further reinforce this trend. Moreover, frequent product approvals and new launches from leading players continue to strengthen North America's market position. These dynamics are anticipated to maintain the region's dominance throughout the forecast period of 2025–2032. A key growth driver in the region is the increasing volume of aesthetic procedures, reflecting the rising demand for non-surgical treatments that deliver quick results with minimal recovery time. This surge is fueled by greater awareness, societal acceptance of cosmetic improvements, and a growing elderly population seeking effective anti-aging solutions. In addition, major industry players are actively investing in R&D to develop advanced dermal filler products tailored for regional needs. For instance, in June 2023, Galderma received FDA approval for Restylane® Eyelight, specifically designed to treat under-eye hollows in adults over 21. It is the first and only HA filler in the U.S. featuring NASHA® Technology to restore under-eye volume and deliver natural results. Similarly, in February 2022, Allergan Aesthetics, an AbbVie company, secured FDA approval for JUVÉDERM® VOLBELLA® XC for treating infraorbital hollows in adults over 21. This product also serves as a lip augmentation solution and helps correct perioral lines, enhancing overall facial aesthetics. Together, the growing demand for cosmetic procedures and strategic product innovations are fueling the dermal fillers market in North America, solidifying its status as a leading region in the global market. To know more about why North America is leading the market growth in the dermal fillers market, get a snapshot of the Dermal Fillers Market Outlook Dermal Fillers Market Dynamics The dermal fillers market is experiencing significant growth, driven primarily by the increasing demand for minimally invasive aesthetic procedures. Rising awareness about cosmetic enhancements and the desire for youthful appearances have fueled the adoption of dermal fillers across various demographics. Factors such as the aging global population, especially in developed economies, and growing disposable incomes in emerging markets have further contributed to market expansion. These procedures are preferred for their relatively quick recovery time and non-surgical nature, which aligns with the current trend toward less invasive treatment options. Technological advancements in dermal filler products have also played a crucial role in shaping market dynamics. Innovations in filler composition, including the introduction of hyaluronic acid-based and biostimulatory fillers, have improved safety profiles, longevity, and natural results. Moreover, ongoing research and development efforts by key players to develop fillers with longer-lasting effects and fewer side effects continue to enhance product appeal. These advancements have not only expanded the scope of applications but have also increased patient satisfaction, encouraging repeat procedures and contributing to market growth. Regulatory approvals and favorable reimbursement policies in certain regions further support the expansion of the dermal fillers market. However, stringent regulations in countries with established healthcare systems can act as barriers for new entrants. Additionally, the rise of medical tourism in countries like Thailand, India, and Mexico has created new growth opportunities for service providers and manufacturers, as patients seek affordable yet high-quality aesthetic treatments. Despite these positive trends, the dermal fillers market faces challenges such as the risk of complications, including allergic reactions and improper injections leading to vascular occlusion. Additionally, the availability of counterfeit or substandard products in some markets poses safety concerns and threatens consumer confidence. Competition from alternative aesthetic procedures like botulinum toxin injections and energy-based devices also adds pressure to the market. Nevertheless, continuous innovation, increasing social acceptance, and the growing influence of social media on beauty standards are expected to sustain robust growth in the coming years. Get a sneak peek at the dermal fillers market dynamics @ Dermal Fillers Market Trends Report Metrics Details Coverage Global Study Period 2022–2032 Dermal Fillers Market CAGR ~8% Dermal Fillers Market Size by 2032 ~USD 12 Billion Key Dermal Fillers Companies AbbVie Inc., Galderma, Merz Pharma, Tiger BioSciences, Teoxane SA, Crown Laboratories, Inc., Prollenium Medical Technologies, Inc., Johnson & Johnson Services, Inc., Anika Therapeutics, Inc., Fillmed, VIVACY Laboratories, Sinclair, Medytox, HUGEL, Inc., Ipsen Pharma, Evolus, Inc., Symatese, LG Chem, KORU Pharma Co., LTD., BIOPLUS CO., LTD., among others Dermal Fillers Market Assessment Dermal Fillers Market Segmentation Dermal Fillers Market Segmentation By Product Type: Biodegradable Fillers and Non-Biodegradable Fillers Dermal Fillers Market Segmentation By Route of Material: Hyaluronic Acid (HA), Calcium hydroxylapatite (CaHA), Poly-L-lactic acid (PLLA), Polymethylmethacrylate (PMMA), and Others Dermal Fillers Market Segmentation By Route of Gender: Male and Female Dermal Fillers Market Segmentation By End-User: Hospitals, Dermatology Clinics, and Others Dermal Fillers Market Segmentation By Geography : North America, Europe, Asia-Pacific, and Rest of World Porter's Five Forces Analysis, Product Profiles, Case Studies, KOL's Views, Analyst's View Which MedTech key players in the dermal fillers market are set to emerge as the trendsetter explore @ Dermal Fillers Analysis Table of Contents 1 Dermal Fillers Market Report Introduction 2 Dermal Fillers Market Executive Summary 3 Competitive Landscape 4 Regulatory Analysis 5 Dermal Fillers Market Key Factors Analysis 6 Dermal Fillers Market Porter's Five Forces Analysis 7 Dermal Fillers Market Layout 8 Dermal Fillers Market Company and Product Profiles 9 KOL Views 10 Project Approach 11 About DelveInsight 12 Disclaimer & Contact Us Interested in knowing the dermal fillers market by 2032? Click to get a snapshot of the Dermal Fillers Market Analysis Related Reports Aesthetic Implants Market Aesthetic Implants Market Insights, Competitive Landscape, and Market Forecast – 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key aesthetic implants companies, including POLYTECH Health & Aesthetics GmbH, Sientra, Inc, Surgiform Innovative Surgical Products, GC Aesthetics, Dentsply Sirona, Institut Straumann AG, AVINENT, AbbVie, Establishment Labs S.A., Mentor (Johnson & Johnson Medical Ltd), 3M, Zimmer Biomet, Alpha Aesthetics, Symatese, Integra LifeSciences, Sebbin, IDEAL IMPLANT INCORPORATED, Lattice Medical, CEREPLAS, Guangzhou Wanhe Plastic Material Co Ltd, among others. Medical Aesthetic Devices Market Medical Aesthetic Devices Market Insights, Competitive Landscape, and Market Forecast – 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key medical aesthetic devices companies, including Johnson & Johnson, HansBioMed., AbbVie Inc., Sebbin, Sientra, Inc., POLYTECH Health & Aesthetics GmbH, Suneva Medical, Hanson Medical Inc., SurgiSil, Surgiform Technologies LLC, Alma Lasers, Candela Medical., Lumenis., Cutera., Sciton Inc, Merz Pharma GmbH & Bausch Health Companies Inc., Venus Concept., TRIA BEAUTY, Cynosure Inc., GALDERMA, among others. Aesthetic Thread Market Aesthetic Thread Market Insights, Competitive Landscape, and Market Forecast – 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key aesthetic thread companies, including Aptos International Ltd, Intraline, Healux Corporation, Croma Pharma GambH, Les Encres Cosmetic Threads, W & O Medical Esthetics Gmbh, Hyundae Meditechh Co. Ltd., N-Finders Co., Ltd., Nova Threads, Savia medical, Metro Korea Co., Ltd., RIVER AESTHETICS, Spring Thread, RELIFE S.r.l., Sinclair, MINT™, PDO MAX, Promoitalia, EWELL Medical., illari Threads, among others. Aesthetic Lasers Market Aesthetic Lasers Market Insights, Competitive Landscape, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key aesthetic lasers companies, including Boston Scientific Corporation, Candela Medical, Lynton Lasers, Lutronic, Fotona, Alma Lasers, Sciton, Astanza Laser, Konmison, AMI INC., Lumibird Medical (Ellex), Cutera, biolitec® Holding GmbH & Co KG, Cartessa Aesthetics, Beagle E-Comm Private Limited, WON TECH Co., Ltd., Attikouris Enterprises Ltd., Aftab Forouzan Aria Company, SL LASERS, Reveal Lasers LLC, among others. Energy-Based Aesthetic Devices Market Energy-Based Aesthetic Devices Market Insights, Competitive Landscape, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key energy-based aesthetic devices companies, including Alma Lasers, Candela Medical, Lumenis, Cutera, Hologic Inc., Sciton Inc., Merz Pharma GmbH & Bausch Health Companies Inc., Venus Concept, TRIA BEAUTY, Cynosure Inc., SharpLight Technologies Inc., Lutronic, Fotona, among others. DelveInsight's Pharma Competitive Intelligence Service: Through its CI solutions, DelveInsight provides its clients with real-time and actionable intelligence on their competitors and markets of interest to keep them stay ahead of the competition by providing insights into the latest therapeutic area-specific/indication-specific market trends, in emerging drugs, and competitive strategies. These services are tailored to the specific needs of each client and are delivered through a combination of reports, dashboards, and interactive presentations, enabling clients to make informed decisions, mitigate risks, and identify opportunities for growth and expansion. Other Business Pharmaceutical Consulting Services Healthcare Conference Coverage Pipeline Assessment Healthcare Licensing Services Discover how a mid-pharma client gained a level of confidence in their soon-to-be partner for manufacturing their therapeutics by downloading our Due Diligence Case Study About DelveInsight DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
Yahoo
19 hours ago
- Yahoo
Crinetics Pharmaceuticals, Inc. (CRNX)' Oral Acromegaly Drug Nears FDA Decision After Strong Phase 3 Data
We recently compiled a list of Crinetics Pharmaceuticals, Inc. stands fifth on our list. Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) stands fifth on our list among the best future growth stocks to buy now. It is a clinical-stage biopharmaceutical company focused on developing oral, small-molecule therapies for rare endocrine diseases and tumors. Its lead candidate, PALSONIFY (paltusotine), is an investigational once-daily oral somatostatin receptor type 2 (SST2) agonist being developed for acromegaly. At the July 2025 ENDO Annual Meeting, Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) presented long-term data from the open-label extensions of its PATHFNDR-1 and PATHFNDR-2 Phase 3 trials, showing that PALSONIFY maintained durable IGF-1 control, reduced symptom burden, and had a consistent safety profile. These findings strengthen its case as a next-generation oral alternative to current injectable therapies, which are the standard of care for acromegaly. The company is now approaching a major inflection point, with a PDUFA date set for late 2025, potentially making PALSONIFY the first oral treatment approved for acromegaly. This would represent a significant shift in disease management and convenience for patients. A scientist in a laboratory looking into a microscope, researching advances in biopharmaceuticals for central nervous system disorders. Beyond PALSONIFY, Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) is advancing other pipeline programs, including Atumelnant, aimed at treating congenital adrenal hyperplasia and ACTH-dependent Cushing's syndrome, as well as several early-stage endocrine disorder therapies. The corporation also expanded its workforce in July 2025, granting equity awards to 46 new employees to support future growth. While we acknowledge the potential of GOOGL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Sign in to access your portfolio
